NCT06598839 is a NA clinical trial of Thymosin Alpha1 in Non Small Cell Lung Cancer, sponsored by Yousheng Mao.

Who is sponsoring NCT06598839?

NCT06598839 is sponsored by Yousheng Mao.

What drugs are being tested in NCT06598839?

Interventions in NCT06598839: Thymosin Alpha1.

What condition does NCT06598839 study?

NCT06598839 studies Non Small Cell Lung Cancer.

Is NCT06598839 still recruiting?

NCT06598839 is currently recruiting now. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT06598839

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immuno-effect of Tα1 for Stage I NSCLC

Recruiting now NA Last updated 19 September 2024

What this trial tests

NA trial testing Thymosin Alpha1 in Non Small Cell Lung Cancer in 40 participants. Currently enrolling.

Timeline

30 June 2024

Primary endpoint
30 September 2025

30 December 2025

Quick facts

Lead sponsor	Yousheng Mao
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	30 June 2024
Primary completion	30 September 2025
Estimated completion	30 December 2025
Sites	1 location across China

Drugs / interventions tested

Thymosin Alpha1 — full drug profile →

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

Yousheng Mao — full company profile →

Who can join

Adults 18 to 75, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the effect of thymosin alpha 1 (Tα1) on postoperative peripheral blood circulating tumor cells and immunosenescence in patients with early-stage non-small cell lung cancer (NSCLC).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeting T-cell Aging to Remodel the Aging Immune System and Revitalize Geriatric Immunotherapy.
Chen M, Su Z, Xue J. · · 2025 · cited 6× · PMID 40153576 · DOI 10.14336/ad.2025.0061

Verify or expand the search:

Other trials of Thymosin Alpha1

Trials testing the same drug.

NCT06139419 — The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for L · Phase 2 · active not recruiting
NCT05487469 — Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass · NA · unknown
NCT04901104 — Long-term Prognosis of Patients With Sepsis After Immunotherapy · not yet recruiting
NCT05086614 — Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer · Phase 3 · recruiting
NCT04524169 — Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain · Phase 4 · unknown

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06598839 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yousheng Mao
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06598839.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing